A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Coya Therapeutics (COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a pharmaceutical company with a market capitalization of $22.74 million, has entered into a material definitive agreement and closed a private investment in ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage ... In addition, we announced our second lead pipeline program for the treatment of acromegaly with clinical development ...

Company to present pipeline update at 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- BOSTON, January 09, 2025--(BUSINESS WIRE)--Nimbus Therapeutics ...

Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline ... strategy to lead in immune-mediated disease therapeutics and is complemented by their ...

pipeline, and anticipated milestones for 2025 and beyond at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT. Nimbus Therapeutics is a clinical-stage ...

Company to present pipeline update at 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT -- Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a ...

Matalan are a UK value-retailer for fashion and homeware, with over 230 stores across the country. They are an important client for Reveal: the first to take body-worn cameras for shopfloor colleagues ...